Retrospective evaluation of the dose equivalence of Botox and Dysport in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story

Anna Rita Bentivoglio, Alfonso Fasano, Ialongo Ta`Mara, Francesco Bove, Francesca De Nigris

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

19 Citazioni (Scopus)

Abstract

Botox(®) and Dysport(®) are the preparations of botulinum neurotoxin most widely used for therapeutic purposes. Several studies have addressed the topic of the equivalency ratio (D/B ratio) to be used in clinical practice and whether a reliable value exists is still a matter of debate. To this purpose, we ideated a novel paradigm by retrospectively examining the patients affected by hemifacial spasm and blepharospasm. We compared the pairs of treatments with a switch from one brand to the other undergone by the same patient in consecutive sessions with overlapping clinical outcome. Out of 2006 treatments, we found 51 treatment pairs. D/B ratio was extremely variable (range 1.2-13.3) and in most cases (65%) it was between 1:3 and 1:5. In conclusion, even if the 1:4 ratio might be reliable for clinical purpose, a true bioequivalence between Dysport(®) and Botox(®) might not exist due to the intrinsic difference in their pharmacokinetic properties.
Lingua originaleEnglish
pagine (da-a)261-267
Numero di pagine7
RivistaNeurological Sciences
DOI
Stato di pubblicazionePubblicato - 2011

Keywords

  • Blepharospasm
  • Botulinum toxin
  • Dose equivalence ratio
  • Hemifacial spasm

Fingerprint

Entra nei temi di ricerca di 'Retrospective evaluation of the dose equivalence of Botox and Dysport in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story'. Insieme formano una fingerprint unica.

Cita questo